Sol-Gel Technologies (SLGL) Receivables (2019 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Receivables of $1.1 million for Q1 2026, down 72.52% year-over-year from $3.9 million in Q1 2025, and down 45.78% quarter-over-quarter from $2.0 million in Q4 2025.
Sol-Gel Technologies (SLGL) Receivables (2019 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Receivables for 8 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 72.52% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (down 72.52% YoY), while the FY2025 annual figure was $2.0 million, down 45.26% from the prior year.
- Receivables retreated to $1.1 million in Q1 2026 per SLGL's latest filing, from $2.0 million in the prior quarter.
- Across five years, Receivables topped out at $10.8 million in Q3 2022 and bottomed at $62000.0 in Q4 2022.
- Historically, Receivables has averaged $5.2 million across 5 years, with a median of $4.8 million in 2023.
- On a YoY basis, Receivables climbed as much as 1268.27% in 2022 and fell as far as 99.53% in 2022.
- Sol-Gel Technologies' Receivables stood at $62000.0 in 2022, then surged by 508.06% to $377000.0 in 2023, then jumped by 853.58% to $3.6 million in 2024, then slumped by 45.26% to $2.0 million in 2025, then plunged by 45.78% to $1.1 million in 2026.
- Business Quant data shows SLGL's Receivables at $1.1 million in Q1 2026, $2.0 million in Q4 2025, and $9.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 1.97 Mn |
| Sep 30, 2025 | 9.85 Mn |
| Jun 30, 2025 | 10.04 Mn |
| Mar 31, 2025 | 3.88 Mn |
| Dec 31, 2024 | 3.60 Mn |
| Sep 30, 2024 | 7.02 Mn |
| Jun 30, 2024 | 6.06 Mn |
| Mar 31, 2024 | 869,000.00 |
| Dec 31, 2023 | 377,000.00 |
| Jun 30, 2023 | 2.21 Mn |
| Mar 31, 2023 | 5.81 Mn |
| Dec 31, 2022 | 62,000.00 |
| Sep 30, 2022 | 10.78 Mn |
| Jun 30, 2022 | 10.18 Mn |
| Mar 31, 2022 | 9.66 Mn |
| Dec 31, 2021 | 13.07 Mn |
| Sep 30, 2021 | 1.39 Mn |
| Jun 30, 2021 | 956,000.00 |
| Mar 31, 2021 | 706,000.00 |